TORONTO, ON, CANADA (June 16, 2017)- Cyclica Inc. is pleased to announce the appointment of John F. Conway to its Scientific Advisory Board (SAB).
John brings to Cyclica his deep expertise in computational drug discovery and cheminformatics, as well as his extensive 25+ years of experience within the pharmaceutical industry. Currently, John serves as Global Director of R&D Data Science and Informatics Strategy at LabAnswer, where he specializes in R&D Data and Cloud Strategies in the life sciences and related industries. Prior to this role, John held leadership roles at Schrödinger and Accelrys (now BIOVIA), as well as Director of Cheminformatics and Structural Biology at GlaxoSmithKline, and Sr. Scientific Programmer and Informatics at Merck and Co. Inc. He attended Penn State University for Biochemistry and then Lehigh University for Molecular and Cellular Biology, and has spent his career becoming an expert in scientific informatics, computational approaches and analytics.
Naheed Kurji, Cyclica’s President and CEO, is excited for Mr. Conway’s addition to the SAB and had this to say, “Over the past 12 months, we have attracted global leaders to support Cyclica’s growth - first with the appointment of Dr. Rick Panicucci to our SAB, then with the appointment of Dr. Mostafa Analoui to our Board of Directors. Similar to our excitement with those appointments, we are thrilled to have John join our SAB. There are very few people that I have met over the past few years who are as thoughtful in their approach, as dedicated to the science, and as deeply entrenched on the business side as well. Our vision as a company is to be an integral utility platform in the pharma R&D value chain. To achieve this, we seek to attract the best, brightest, and most committed talent, and John fits that model very well. I am confident that his impact on the company will be immediate and profound.”
John had this to say about his appointment, “I’ve gotten to know the Cyclica team well over the past few months. What impressed me the most, beyond their dynamic team, perpetual energy and focused strategy, is their innovative thinking around long-standing problems in the pharmaceutical space. I fundamentally believe that they are on the right path to make a significant positive impact in the space, which is desperately needed. I look forward to working with my colleagues on the SAB and the Cyclica team to get our science and technology like the Ligand Express™ platform broadly adopted and consistently used in the market.”
— 30 —
Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities. www.cyclicarx.com